Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness
Author:
Publisher
Elsevier BV
Subject
Clinical Neurology,Neurology,General Medicine
Reference16 articles.
1. Ocrelizumab: A Review in Multiple Sclerosis;Syed;CNS Drugs,2018
2. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects;Sorensen;Ther Adv Neurol Disord,2016
3. Kappos L; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis;Hauser;N Engl J Med,2017
4. ORATORIO Clinical Investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis;Montalban;N Engl J Med,2017
5. Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders;Ellrichmann;J Neurol,2019
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity;Multiple Sclerosis Journal;2023-11-09
2. Half-dose ocrelizumab in selected patients with relapsing–remitting multiple sclerosis;Acta Neurologica Belgica;2023-06-10
3. Ocrelizumab extended‐interval dosing in multiple sclerosis during SARS‐CoV‐2 pandemic: a real‐world experience;European Journal of Neurology;2023-06-05
4. Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis;Med;2023-06
5. Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis;Journal of Neurology, Neurosurgery & Psychiatry;2023-01-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3